If you’ve been watching Pfizer’s dealmaking over the past few years, you may have noticed a trend: It likes buys that bring in new sales, and quickly. According to company execs, that’s a trend they intend to continue.
Pfizer’s “bias” has been toward buys that can provide revenue growth “now or soon,” CFO Frank D’Amelio said during a Tuesday fireside chat at the J.P. Morgan Healthcare Conference. Its $16 billion Hospira buy was “now.” Its $14 billion Medivation deal was “now.” And Anacor, which Pfizer nabbed for $5 billion in June—just six months or so before the FDA approved blockbuster hopeful Eucrisa—“was soon,” he pointed out.
The company has done some earlier-stage deals, D’Amelio noted, but if pressed to answer for the company’s future moves—as interviewer and J.P. Morgan analyst Chris Schott made sure he was—D’Amelio would say that bias is still intact.
It’s no surprise that marketed or near-to-market products have been Pfizer’s focus since its mammoth deal for self-proclaimed “growth pharma” Allergan fell through last April. Products including oncology hotshot Ibrance and pneumococcal pneumonia vaccine Prevnar 13 have been red hot, but some analysts question how much growth those products have left after penetrating their markets.
Meanwhile, pharma-watchers eager to see M&A pick up the pace have their eyes on Pfizer, which stands to come up big if widely expected tax reform makes it cheaper for the company to access its overseas coffers.
That scenario would give the pharma giant “huge capital firepower,” D’Amelio admitted.
But that doesn’t mean the company will press pause now, in anticipation of any future access to that cash. “If we see a deal we think works today with the cards we’ve been dealt, I don’t know why would we would wait,” he said.
By Carly Helfand
Source: Fierce Pharma
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.